SGMT
Sagimet Biosciences Inc.
$8.12
+2.26
(+38.57%)
Mkt Cap
259.98M
Volume
49,305,650
52W Range
3.03-11.41
Sector
Healthcare
Beta
3.21
EPS (TTM)
-1.58
P/E Ratio
-3.75
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2.00M | 0 | 0 | 0 | 0 |
| Net Income | (51.04M) | (45.57M) | (27.88M) | (30.50M) | (24.44M) | (11.37M) | (14.26M) |
| EPS | -1.58 | -1.45 | -1.53 | -1.38 | -1.10 | -0.51 | -0.64 |
| Free Cash Flow | (45.65M) | (42.44M) | (23.77M) | (24.49M) | (21.71M) | (10.42M) | (10.55M) |
| FCF / Share | -1.41 | -1.35 | -1.31 | -1.10 | -0.98 | -0.47 | -0.48 |
| Operating CF | (45.65M) | (42.44M) | (23.77M) | (24.49M) | (21.71M) | (10.42M) | (10.55M) |
| Total Assets | 116.48M | 160.26M | 96.72M | 33.03M | 59.03M | 68.96M | 11.16M |
| Total Debt | 78,000 | 78,000 | 65,000 | 211,000 | 348,000 | 210,000 | 341,000 |
| Cash & Equiv | 35.02M | 75.84M | 75.14M | 158,000 | 56.73M | 68.70M | 10.21M |
| Book Value | 111.38M | 155.81M | 91.06M | (186.95M) | (158.26M) | (135.91M) | (125.31M) |
| Return on Equity | -0.46 | -0.29 | -0.31 | N/A | N/A | N/A | N/A |
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.00M | 0 | 0 |
| Net Income | (9.57M) | (12.91M) | (10.39M) | (18.18M) | (16.20M) | (14.62M) | (8.12M) | (6.63M) | (8.15M) | (6.35M) | (6.79M) | (6.59M) |
| EPS | -0.30 | -0.40 | -0.32 | -0.56 | -0.50 | -0.45 | -0.25 | -0.23 | -0.45 | -0.35 | -0.31 | -0.30 |
| Free Cash Flow | (11.83M) | (10.18M) | (9.10M) | (14.54M) | (11.02M) | (19.57M) | (5.63M) | (6.21M) | (7.08M) | (3.88M) | (5.72M) | (7.08M) |
| FCF / Share | -0.37 | -0.31 | -0.28 | -0.45 | -0.34 | -0.61 | -0.18 | -0.21 | -0.39 | -0.21 | -0.26 | -0.32 |
| Operating CF | (11.83M) | (10.18M) | (9.10M) | (14.54M) | (11.02M) | (19.57M) | (5.63M) | (6.21M) | (7.08M) | (3.88M) | (5.72M) | (7.08M) |
| Total Assets | 116.48M | 128.40M | 137.41M | 146.17M | 160.26M | 174.78M | 189.02M | 194.53M | 96.72M | 102.92M | 21.50M | 27.25M |
| Total Debt | 78,000 | 115,000 | 152,000 | 39,000 | 78,000 | 116,000 | 153,000 | 26,000 | 65,000 | 103,000 | 140,000 | 176,000 |
| Cash & Equiv | 35.02M | 32.50M | 42.33M | 64.72M | 75.84M | 77.01M | 95.96M | 176.78M | 75.14M | 101.84M | 18.51M | 12.34M |
| Book Value | 111.38M | 119.25M | 130.16M | 138.99M | 155.81M | 170.68M | 183.29M | 190.02M | 91.06M | 97.88M | (198.41M) | 21.93M |
| Return on Equity | -0.09 | -0.11 | -0.08 | -0.13 | -0.10 | -0.09 | -0.04 | -0.03 | -0.09 | -0.06 | N/A | -0.30 |
SGMT News
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
Sagimet Biosciences (NASDAQ:SGMT) vs. AC Immune (NASDAQ:ACIU) Financial Survey
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne